Development of a Patient-Reported Outcome Measure for Chronic Hypoparathyroidism

Authors:

Abstract
A patient-reported outcome (PRO) measure specific to chronic hypoparathyroidism is lacking to facilitate the evaluation of treatment. A PRO measure that followed the recommendations of the US Food and Drug Administration (FDA) PRO guidance was created to address key hypoparathyroidism symptoms.
Funding Information
  • Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies

This publication has 14 references indexed in Scilit: